Bioavailability describes the extent and rate at which an active substance enters the systemic circulation from a dosage form and is then available for further distribution. It is a pharmacokinetic characteristic of a defined dosage form, dose, and administration situation. Bioavailability is derived from concentration-time data and must be distinguished from bioequivalence as a comparative assessment between medicinal products.
Extent and rate of exposure
Following extravascular administration, an active substance must first be released and absorbed. The area under the concentration-time curve, or AUC, describes the extent of systemic exposure. The maximum observed concentration, Cmax, and the time at which it occurs provide information about the rate of uptake. Which parameters are relevant to a specific question depends on the active substance, dosage form, route of administration, and therapeutic window. Concentration-time profiles are generated through planned sampling and a validated bioanalytical method.
Following intravenous administration, the active substance enters the systemic circulation immediately; it is therefore often used as the reference route. With oral administration, incomplete absorption and presystemic metabolism may reduce exposure. In the first-pass effect, some of the active substance is metabolized in the intestinal wall and, in particular, in the liver before reaching the systemic circulation. Lower oral bioavailability does not necessarily indicate inadequate treatment, but it does influence dose, variability, and formulation strategy. Observed bioavailability may also vary between individuals and administration situations, which is why study conditions and concomitant factors must be documented precisely.
Absolute and relative bioavailability
Absolute bioavailability relates systemic exposure after non-intravenous administration to exposure after intravenous administration of the same active substance, taking the administered doses into account. It therefore answers the question of what proportion of the dose becomes systemically available. It is particularly useful when absorption, the first-pass effect, or a new route of administration is being investigated. However, an intravenous reference is not available or appropriate in every development program.
Relative bioavailability compares the exposure of two dosage forms or administration situations involving the same active substance. For example, it may compare a new formulation with an earlier formulation, different strengths, or conditions with and without food. The result describes a relative difference in exposure; it does not yet provide a regulatory statement on whether two medicinal products are recognized as bioequivalent. For biological medicinal products, other considerations regarding comparability may also be relevant than for conventional small-molecule active substances.
Distinction from bioequivalence
Bioavailability is a characteristic or measurement of active-substance exposure following a specific administration. Bioequivalence, by contrast, is a formal comparative assessment between a test and a reference formulation. It is intended to demonstrate that, under predefined conditions, there is no relevant difference in the extent and rate of availability. The EMA Guideline on the Investigation of Bioequivalence describes the study principles, comparison parameters, and statistical requirements for this purpose.
To demonstrate bioequivalence, the AUC and Cmax of the test and reference products are typically compared. A single measurement of absolute bioavailability does not replace this comparison. Conversely, a bioequivalence study uses pharmacokinetic measures of bioavailability but answers a different question: not “how much active substance becomes systemically available?”, but “is the exposure from the test formulation sufficiently similar to that from the reference?”. This distinction is essential for the protocol, statistics, and regulatory submission.
Relevance for clinical trials
Bioavailability data guide clinical development from the initial formulation selection through to dose recommendations. They can explain why exposures differ between dosage forms, fed and fasted conditions, or patient groups. For robust decision-making, dose administration, meals, sampling windows, handling of deviations, and bioanalysis must be planned in advance. Authorities assess whether the data actually cover the requested formulation and intended clinical use and whether the pharmacokinetic analysis is comprehensible.
Full-service CROs such as Mediconomics support the design of bioavailability and relative comparison studies, preparation of the protocol, and coordination of the study site, sample logistics, and bioanalysis. This also includes monitoring dosing and sampling procedures, data management for concentration data, pharmacokinetic analysis by biostatistics, and medical writing for clinical study reports and regulatory documents.
Frequently Asked Questions (FAQ)
Is bioavailability after intravenous administration always 100 percent?
With regard to immediate entry into the systemic circulation, intravenous administration serves as the reference for complete systemic availability. Subsequent distribution, metabolism, and elimination of the active substance are separate pharmacokinetic processes.
Why are both AUC and Cmax important?
AUC describes the extent of exposure over time. Cmax describes the highest measured concentration and may be relevant to the rate of uptake and concentration peaks. Both measures can address different development questions.
Is higher bioavailability always advantageous?
No. Greater exposure may increase efficacy but may also increase the likelihood of dose-dependent adverse effects. What matters is controllable exposure that is appropriate for the therapeutic objective and has acceptable variability.
Regulatory references
- EMA, Guideline on the Investigation of Bioequivalence – describes principles for comparison parameters and the analysis of bioequivalence studies.
- ICH E4, Dose-Response Information to Support Drug Registration – places the importance of dose-response information in the context of drug development.
- ICH M3(R2), Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals – addresses the role of nonclinical pharmacokinetics and toxicokinetics in clinical studies.